Mario Otto, MD, PhD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthSpecialties
Clinics
Hospital Affiliation(s)
American Family Children's Hospital
UnityPoint Health - Meriter
St. Mary's Hospital
UW School of Medicine and Public Health
| Department of Pediatrics |
Professional Certifications and Education
| Board Certification |
Pediatrics
Pediatric Hematology-Oncology |
| Fellowship |
St. Jude Children's Research Hospital, Memphis, TN
|
| Residency |
Children's University Hospital, Tuebingen, Germany
Akron Children's Hospital, Akron, OH |
| Internship |
Children's University Hospital, Tuebingen, Germany
|
| Medical School |
University of Tuebingen School of Medicine, Germany
|
Languages Spoken
| German |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
| Research |
Dr. Otto is pursuing novel, alternative approaches to treat childhood cancer. His research includes areas such as adoptive immunotherapies, nano-oncology and stem cell graft design for the transplant setting. |
PubMed Articles
-
Bednarz B Grudzinski J Marsh I Besemer A Baiu D Weichert J Otto M
Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents. Health Phys . 2018 Apr;114(4):450-459
[PubMed ID: 29481536]
-
Baiu DC Marsh IR Boruch AE Shahi A Bhattacharya S Jeffery JJ Zhao Q Hall LT Weichert JP Bednarz BP Otto M
Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog. J Nucl Med . 2018 Feb;59(2):244-250
[PubMed ID: 28747518]
-
Jiao P Otto M Geng Q Li C Li F Butch ER Snyder SE Zhou H Yan B
Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct. J Mater Chem B . 2016 Jan 20;4(3):513-520
[PubMed ID: 27087966]
-
Marino R Baiu DC Bhattacharya S Titz B Hebron E Menapace BD Singhal S Eickhoff JC Asimakopoulos F Weichert JP Otto M
Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastoma. Am J Cancer Res . 2015;5(11):3422-35
[PubMed ID: 26807322]
-
Baiu DC Artz NS McElreath MR Menapace BD Hernando D Reeder SB Grüttner C Otto M
High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine (Lond) . 2015 Oct;10(19):2973-2988
[PubMed ID: 26420448]
-
McDowell KA Hank JA DeSantes KB Capitini CM Otto M Sondel PM
NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol . 2015 Mar;37(2):79-93
[PubMed ID: 25590232]
-
Xu Y Baiu DC Sherwood JA McElreath MR Qin Y Lackey KH Otto M Bao Y
Linker-free conjugation and specific cell targeting of antibody functionalized iron-oxide nanoparticles. J Mater Chem B . 2014 Oct 7;2(37):6198-6206
[PubMed ID: 26660881]
-
Navid F Sondel PM Barfield R Shulkin BL Kaufman RA Allay JA Gan J Hutson P Seo S Kim K Goldberg J Hank JA Billups CA Wu J Furman WL McGregor LM Otto M Gillies SD Handgretinger R Santana VM
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol . 2014 May 10;32(14):1445-52
[PubMed ID: 24711551]
-
Capitini CM Otto M DeSantes KB Sondel PM
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol . 2014;10(9):1659-78
[PubMed ID: 25145434]
-
Baiu DC Brazel CS Bao Y Otto M
Interactions of iron oxide nanoparticles with the immune system: challenges and opportunities for their use in nano-oncology. Curr Pharm Des . 2013;19(37):6606-21
[PubMed ID: 23621531]
-
Otto M Shulkin BL Kundu M Sandlund JT Snyder SE Metzger ML
Histiocyte-rich xanthomatous pseudotumor mimicking relapse on positron emission tomography imaging in an adolescent with primary mediastinal diffuse large B-cell lymphoma. J Pediatr Hematol Oncol . 2012 Apr;34(3):232-5
[PubMed ID: 22082744]
-
Jiao P Zhou H Otto M Mu Q Li L Su G Zhang Y Butch ER Snyder SE Jiang G Yan B
Leading neuroblastoma cells to die by multiple premeditated attacks from a multifunctionalized nanoconstruct. J Am Chem Soc . 2011 Sep 7;133(35):13918-21
[PubMed ID: 21827210]
-
Sorkin LS Otto M Baldwin WM 3rd Vail E Gillies SD Handgretinger R Barfield RC Ming Yu H Yu AL
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain . 2010 Apr;149(1):135-42
[PubMed ID: 20171010]
-
Barfield R Chen X Otto M Handgretinger R
Beyond the FACS. Stem Cells . 2007 Nov;25(11):2972
[PubMed ID: 17656640]
-
Otto M Chen X Martin WJ Leung W Knowles J Holladay M Houston J Handgretinger R Barfield RC
Selection of stem cells by using antibodies that target different CD34 epitopes yields different patterns of T-cell differentiation. Stem Cells . 2007 Feb;25(2):537-42
[PubMed ID: 17023516]
-
Otto M Barfield RC Martin WJ Iyengar R Leung W Leimig T Chaleff S Gillies SD Handgretinger R
Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin Cancer Res . 2005 Dec 1;11(23):8486-91
[PubMed ID: 16322312]
-
Chen X Barfield R Benaim E Leung W Knowles J Lawrence D Otto M Shurtleff SA Neale GA Behm FG Turner V Handgretinger R
Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. Blood . 2005 Jan 15;105(2):886-93
[PubMed ID: 15358630]
-
Otto M Barfield RC Iyengar R Gatewood J Müller I Holladay MS Houston J Leung W Handgretinger R
Human gammadelta T cells from G-CSF-mobilized donors retain strong tumoricidal activity and produce immunomodulatory cytokines after clinical-scale isolation. J Immunother . 2005 Jan-Feb;28(1):73-8
[PubMed ID: 15614047]
